Cs1001 combined with chemotherapy for esophageal squamous cell carcinoma
-
Last Update: 2020-01-08
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Cornerstone Pharmaceutical (Suzhou) Co., Ltd According to the data of GLOBOCAN in 2018, 307 thousand cases of new cases of esophageal cancer occur in China every year, and 283 thousand cases of deaths, incidence rate and mortality rate are fifth and fourth respectively in China 90% of esophageal cancer patients in China are esophageal squamous cell carcinoma, and about 70% of esophageal squamous cell carcinoma patients have local late or late metastasis at the time of diagnosis At present, the standard first-line treatment for advanced esophageal squamous cell carcinoma is dual drug chemotherapy with platinum drugs, but the curative effect is very limited The data showed that the objective response rate (ORR) was about 35%, the median progression free survival (PFS) was less than half a year, the median overall survival (OS) was less than 1 year, and the patients had no other effective treatment options Cs1001 is a monoclonal antibody against PD-L1 developed by cornerstone pharmaceutical According to the research data published at the annual meeting of Chinese society of Clinical Oncology (CSCO) in 2019, as of July 1, 2019, in the phase 1b clinical trial of cs1001 combined with FP for first-line esophageal squamous cell carcinoma, Orr reached 77.8%, with sustained remission and good overall safety and tolerance.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
